Jim Cramer Says AMD Under $150 Would Be ‘Terrific’ But ‘It Doesn’t Have What Nvidia Has’
The semiconductor landscape has been witnessing intense competition, with Nvidia's dominance in the AI sector challenging rivals like AMD and Intel.
Alaska Airlines Acquires Training Facility Once Owned By Boeing: Details
Alaska Air Group has acquired a $85.75 million facility from Unico Properties, spanning 19 acres with a 600,000-square-foot building.
What’s Going On With Palantir Technologies Stock Today?
Palantir Technologies surges premarket following a significant Department of Defense contract award for AI-enabled solutions, signaling enhanced warfighter adoption and operational capabilities.
Google’s Ex-CEO Eric Schmidt, Amazon, Salesforce Propel France’s Ambition To Be Global AI Leader
France accounted for approximately 20% of total European AI startup funding in 2023, according to data from Dealroom.
China Cites ‘National Security’ As It Tightens Export Controls On Aviation And Aerospace Equipment Amid US Restrictions
A spokesperson clarified that these rules are not aimed at any particular country or region.
Jail Time For Trump? Alvin Bragg Refuses To Say If Prosecutors Will Pursue The Option: ‘I Did My Job’
Former President Donald Trump has been found guilty on multiple charges. As the legal and political ramifications unfold,…
Oncocyte VitaGraft Kidney Study Results Published In The New England Journal Of Medicine
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with claims
Oncternal Completes Enrollment And Dosing Initiated For 5th Dose Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for
NextCure To Present Phase 1b Data On NC410 And Pembrolizumab Combination at ASCO 2024 June 1, 2024
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a
Ultragenyx Announces Top-Line Results From Phase 3 Study of DTX401 Gene Therapy For Glycogen Storage Disease Type Ia
Treatment with DTX401 resulted in a statistically significant reduction in daily cornstarch intake at Week 48 (p<0.0001) with maintenance of glucose control Company will host investor call today at 5:00 p.m.